Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.

Feng, Gang; Li, Qing; Zhu, Haibo; Jiang, Yanyu; Yuan, Jijun; Fu, Yingxin; Deng, Qi

Feng, Gang; Li, Qing; Zhu, Haibo; Jiang, Yanyu; Yuan, Jijun; Fu, Yingxin; Deng, Qi.

Afiliación

Feng G; Department of Kidney Transplantation, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Li Q; Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Zhu H; Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Jiang Y; Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Yuan J; Shanghai Genbase Biotechnology Co. Ltd., Shanghai, China.
Fu Y; Department of Kidney Transplantation, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Deng Q; Department of Kidney Transplantation, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.

Front Oncol ; 11: 726134, 2021.

Article en En | MEDLINE | ID: mdl-34604065

Palabras clave

T cells; chimeric antigen receptor; diffuse large B-cell lymphoma; post-transplant lymphoproliferative disease; programmed cell death 1

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: Front Oncol Año: 2021 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google